Literature DB >> 8335365

Interleukin-1 (IL-1) receptor antagonist prevents Staphylococcus epidermidis-induced hypotension and reduces circulating levels of tumor necrosis factor and IL-1 beta in rabbits.

K Aiura1, J A Gelfand, J F Burke, R C Thompson, C A Dinarello.   

Abstract

Similar to shock in gram-negative sepsis, shock from gram-positive organisms is mediated, in part, by tumor necrosis factor (TNF) and interleukin-1 (IL-1). In the present study, rabbits were infused with IL-1 receptor antagonist (IL-1ra) prior to and during Staphylococcus epidermidis-induced hypotension. After injection of bacteria, a maximal fall in mean arterial pressure to -42% below baseline occurred at 200 min in vehicle-treated animals compared with a nonsignificant decrease of only 7% in the IL-1ra-treated group (P < 0.01, vehicle versus IL-1ra). A similar attenuation was observed in the fall in systemic vascular resistance (P < 0.05). After the injection of S. epidermidis, TNF levels rose to a peak elevation of 475 +/- 160 U/ml in vehicle-treated rabbits, but in rabbits receiving IL-1ra, maximal TNF levels rose only to 85 +/- 23 U/ml (P < 0.01). Plasma IL-1 beta reached maximal concentrations at 180 min of 364 +/- 71 pg/ml in vehicle-treated animals but only 145 +/- 12 pg/ml in rabbits given IL-1ra (P < 0.05). The reductions in TNF and IL-1 were not due to interference by IL-1ra in the respective assays. In vitro, IL-1ra inhibited S. epidermidis-induced TNF from mononuclear cells by 31% +/- 11%, from spleen cells by 17% +/- 4% (P < 0.05), and from whole blood by 42% +/- 17%. Despite the near reversal of the fall in mean arterial pressure and systemic vascular resistance in IL-1ra-treated rabbits, leukopenia and thrombocytopenia were unaffected. These results demonstrate that IL-1ra blocks shock-like hemodynamic parameters and reduces circulating IL-1 and TNF levels in a model of gram-positive sepsis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8335365      PMCID: PMC281009          DOI: 10.1128/iai.61.8.3342-3350.1993

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  39 in total

1.  Production of interleukin-1-receptor antagonist during experimental endotoxaemia.

Authors:  E V Granowitz; A A Santos; D D Poutsiaka; J G Cannon; D W Wilmore; S M Wolff; C A Dinarello
Journal:  Lancet       Date:  1991-12-07       Impact factor: 79.321

2.  PADGEM protein: a receptor that mediates the interaction of activated platelets with neutrophils and monocytes.

Authors:  E Larsen; A Celi; G E Gilbert; B C Furie; J K Erban; R Bonfanti; D D Wagner; B Furie
Journal:  Cell       Date:  1989-10-20       Impact factor: 41.582

3.  PADGEM-dependent adhesion of platelets to monocytes and neutrophils is mediated by a lineage-specific carbohydrate, LNF III (CD15).

Authors:  E Larsen; T Palabrica; S Sajer; G E Gilbert; D D Wagner; B C Furie; B Furie
Journal:  Cell       Date:  1990-11-02       Impact factor: 41.582

4.  Interleukin-1 (IL-1) receptor blockade reduces endotoxin and Borrelia burgdorferi-stimulated IL-8 synthesis in human mononuclear cells.

Authors:  R Porat; D D Poutsiaka; L C Miller; E V Granowitz; C A Dinarello
Journal:  FASEB J       Date:  1992-04       Impact factor: 5.191

5.  Effect of interleukin-1 (IL-1) blockade on cytokine synthesis: I. IL-1 receptor antagonist inhibits IL-1-induced cytokine synthesis and blocks the binding of IL-1 to its type II receptor on human monocytes.

Authors:  E V Granowitz; B D Clark; E Vannier; M V Callahan; C A Dinarello
Journal:  Blood       Date:  1992-05-01       Impact factor: 22.113

6.  Hospital-acquired bloodstream infections with Staphylococcus epidermidis. Review of 100 cases.

Authors:  S Ponce de Leon; R P Wenzel
Journal:  Am J Med       Date:  1984-10       Impact factor: 4.965

7.  A specific receptor antagonist for interleukin 1 prevents Escherichia coli-induced shock in rabbits.

Authors:  G Wakabayashi; J A Gelfand; J F Burke; R C Thompson; C A Dinarello
Journal:  FASEB J       Date:  1991-03-01       Impact factor: 5.191

8.  Role of endotoxemia in cardiovascular dysfunction and mortality. Escherichia coli and Staphylococcus aureus challenges in a canine model of human septic shock.

Authors:  C Natanson; R L Danner; R J Elin; J M Hosseini; K W Peart; S M Banks; T J MacVittie; R I Walker; J E Parrillo
Journal:  J Clin Invest       Date:  1989-01       Impact factor: 14.808

9.  Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia.

Authors:  Y Fong; K J Tracey; L L Moldawer; D G Hesse; K B Manogue; J S Kenney; A T Lee; G C Kuo; A C Allison; S F Lowry
Journal:  J Exp Med       Date:  1989-11-01       Impact factor: 14.307

10.  Platelet-derived interleukin 1 induces human endothelial adhesion molecule expression and cytokine production.

Authors:  C M Hawrylowicz; G L Howells; M Feldmann
Journal:  J Exp Med       Date:  1991-10-01       Impact factor: 14.307

View more
  10 in total

1.  Differential roles of interleukin-18 (IL-18) and IL12 for induction of gamma interferon by staphylococcal cell wall components and superantigens.

Authors:  R J Stuyt; M G Netea; S H Kim; D Novick; M Rubinstein; B J Kullberg; J W Van der Meer; C A Dinarello
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

2.  Cytokine-mediated inflammatory hyperalgesia limited by interleukin-1 receptor antagonist.

Authors:  J M Cunha; F Q Cunha; S Poole; S H Ferreira
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

3.  Role for intracellular platelet-activating factor in the circulatory failure in a model of gram-positive shock.

Authors:  S J De Kimpe; C Thiemermann; J R Vane
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

Review 4.  Pathophysiology of sepsis-related cardiac dysfunction: driven by inflammation, energy mismanagement, or both?

Authors:  Konstantinos Drosatos; Anastasios Lymperopoulos; Peter Johannes Kennel; Nina Pollak; P Christian Schulze; Ira J Goldberg
Journal:  Curr Heart Fail Rep       Date:  2015-04

5.  Delayed circulatory failure due to the induction of nitric oxide synthase by lipoteichoic acid from Staphylococcus aureus in anaesthetized rats.

Authors:  S J De Kimpe; M L Hunter; C E Bryant; C Thiemermann; J R Vane
Journal:  Br J Pharmacol       Date:  1995-03       Impact factor: 8.739

6.  Beneficial effects of interleukin-6 in neonatal mouse models of group B streptococcal disease.

Authors:  G Mancuso; F Tomasello; M Migliardo; D Delfino; J Cochran; J A Cook; G Teti
Journal:  Infect Immun       Date:  1994-11       Impact factor: 3.441

7.  Why a second look might be worth it: immuno-modulatory therapies in the critically ill patient.

Authors:  Benedikt H Siegler; Thorsten Brenner; Florian Uhle; Sebastian Weiterer; Markus A Weigand; Stefan Hofer
Journal:  J Thorac Dis       Date:  2016-06       Impact factor: 2.895

8.  Decreased mortality of severe acute pancreatitis after proximal cytokine blockade.

Authors:  J G Norman; M G Franz; G S Fink; J Messina; P J Fabri; W R Gower; L C Carey
Journal:  Ann Surg       Date:  1995-06       Impact factor: 12.969

9.  A randomized controlled trial of interleukin-1 receptor antagonist in a rabbit model of ascending infection in pregnancy.

Authors:  R S McDuffie; J K Davies; K K Leslie; S Lee; M P Sherman; R S Gibbs
Journal:  Infect Dis Obstet Gynecol       Date:  2001

Review 10.  New Decade, Old Debate: Blocking the Cytokine Pathways in Infection-Induced Cytokine Cascade.

Authors:  Mahrukh S Rizvi; Alice Gallo De Moraes
Journal:  Crit Care Explor       Date:  2021-03-23
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.